What is Dynavax Technologies Corporation's earnings per share (EPS)?

Dynavax Technologies Corporation (DVAX) reported diluted earnings per share of $0.20 for fiscal year 2024. This represents a 500.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Dynavax Technologies Corporation (DVAX) Financials

DVAX

Trailing 12 months to September 30, 2025

Revenue $330.5M +26.7% YoY

Net Income -$43.4M -311.9% YoY

EPS (Diluted) -$0.37 -384.6% YoY

Free Cash Flow $80.5M +255.3% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2025, ended Sep 30, 2025 Reported Nov 5, 2025 Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2025, filed Nov 5, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DVAX SEC filings page.

Dynavax Technologies Corporation (DVAX) reported $330.5M in revenue over the twelve months to Sep 30, 2025, up 26.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DVAX FY2024 2026-08-30

Dynavax’s dominant mechanic is high gross-margin revenue that converts to cash while operating costs keep reported operating profit near break-even.

The earnings-to-cash relationship is more informative than net income alone: in FY2022, $293M of net income accompanied only $63M of operating cash flow. By contrast, FY2024 produced $67M of operating cash flow against $27M of net income, so cash generation aligned more closely with the modest profit even as operating income remained negative.

The margin shape improved on both sides of the income statement: gross margin widened from 78.4% in FY2023 to 82.2% in FY2024. Operating margin also moved from -15.9% to -1.5%, indicating better gross economics and scale absorption, but not yet a consistently profitable operating engine.

The balance sheet is liquid relative to near-term obligations: the current ratio was 10.8x, while debt-to-equity was 0.7x, indicating limited dependence on leverage. FY2024 financing cash flow was -$102M, including $100M of buybacks, so shareholder distributions drove the financing outflow.

Financial Health Signals

Financial Health Score 54/100

Scored against operating companies for FY2024. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Dynavax Technologies Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Dynavax Technologies Corporation has an operating margin of -1.5%, meaning the company loses $1 on every $100 of revenue. This results in a profitability score of 36/100. This is up from -15.9% the prior year.

Growth

Dynavax Technologies Corporation's revenue surged 19.4% year-over-year to $277.2M, reflecting rapid business expansion. This strong growth earns a score of 1/100.

Leverage

Dynavax Technologies Corporation has a moderate D/E ratio of 0.65. This balance of debt and equity financing earns a leverage score of 56/100.

Liquidity

With a current ratio of 10.80, Dynavax Technologies Corporation holds $10.80 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 98/100.

Cash Flow

Dynavax Technologies Corporation converts 21.7% of revenue into free cash flow ($60.2M). This strong cash generation earns a score of 91/100.

Returns

Dynavax Technologies Corporation's ROE of 4.6% shows moderate profitability relative to equity, earning a score of 43/100. This is up from -1.0% the prior year.

Altman Z-Score Grey Zone

2.73

Dynavax Technologies Corporation scores 2.73, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($1.8B) relative to total liabilities ($389.5M). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

7/8

Dynavax Technologies Corporation passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.44x

For every $1 of reported earnings, Dynavax Technologies Corporation generates $2.44 in operating cash flow ($66.5M OCF vs $27.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

N/A

Dynavax Technologies Corporation reported an operating loss of $4.1M against $6.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$94.9M

YoY+17.7%

QoQ-0.6%

5Y CAGR+47.9%

10Y CAGR+55.0%

Dynavax Technologies Corporation generated $94.9M in revenue in Q3 2025. This represents an increase of 17.7% from the same quarter a year earlier. Against the prior quarter it is down 0.6%.

EBITDA

$22.6M

YoY+100.3%

QoQ+44.0%

Dynavax Technologies Corporation's EBITDA was $22.6M in Q3 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.3% from the same quarter a year earlier. Against the prior quarter it is up 44.0%.

Net Income

$26.9M

YoY+53.0%

QoQ+43.8%

5Y CAGR+43.7%

Dynavax Technologies Corporation reported $26.9M in net income in Q3 2025. This represents an increase of 53.0% from the same quarter a year earlier. Against the prior quarter it is up 43.8%.

EPS (Diluted)

$0.21

YoY+75.0%

QoQ+50.0%

Dynavax Technologies Corporation earned $0.21 per diluted share (EPS) in Q3 2025. This represents an increase of 75.0% from the same quarter a year earlier. Against the prior quarter it is up 50.0%.

Cash & Balance Sheet

Free Cash Flow

$32.6M

YoY+79.9%

QoQ+48.3%

Dynavax Technologies Corporation generated $32.6M in free cash flow in Q3 2025, representing cash available after capex. This represents an increase of 79.9% from the same quarter a year earlier. Against the prior quarter it is up 48.3%.

Cash & Debt

$160.2M

YoY+34.3%

QoQ+61.7%

5Y CAGR+37.4%

10Y CAGR+4.5%

Dynavax Technologies Corporation held $160.2M in cash as of Q3 2025; long-term debt is not reported for that period.

Shares Outstanding

117M

YoY-10.7%

QoQ+0.1%

5Y CAGR+1.3%

10Y CAGR+11.8%

Dynavax Technologies Corporation had 117M shares outstanding in Q3 2025. This represents a decrease of 10.7% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q3 2025.

Margins & Returns

Gross Margin

84.8%

YoY+1.0pp

QoQ-0.5pp

Dynavax Technologies Corporation's gross margin was 84.8% in Q3 2025, indicating the percentage of revenue retained after direct costs. This is up 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.5 percentage points.

Operating Margin

22.4%

YoY+9.9pp

QoQ+7.3pp

Dynavax Technologies Corporation's operating margin was 22.4% in Q3 2025, reflecting core business profitability. This is up 9.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.3 percentage points.

Net Margin

28.4%

YoY+6.6pp

QoQ+8.8pp

5Y change-4.4pp

Dynavax Technologies Corporation's net profit margin was 28.4% in Q3 2025, showing the share of revenue converted to profit. This is up 6.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.8 percentage points.

Return on Equity

5.0%

YoY+2.5pp

QoQ+1.2pp

5Y change-1.3pp

10Y change+19.3pp

Dynavax Technologies Corporation's ROE was 5.0% in Q3 2025, measuring profit generated per dollar of shareholder equity. This is up 2.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.

Capital Allocation

R&D Spending

$19.1M

YoY+32.7%

QoQ+15.0%

5Y CAGR+17.5%

Dynavax Technologies Corporation invested $19.1M in research and development in Q3 2025. This represents an increase of 32.7% from the same quarter a year earlier. Against the prior quarter it is up 15.0%.

Share Buybacks

$572K

QoQ-99.2%

Dynavax Technologies Corporation spent $572K on share buybacks in Q3 2025, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is down 99.2%.

Capital Expenditures

$1.2M

YoY-8.1%

QoQ-14.8%

5Y CAGR+36.1%

10Y CAGR-7.1%

Dynavax Technologies Corporation invested $1.2M in capex in Q3 2025, funding long-term assets and infrastructure. This represents a decrease of 8.1% from the same quarter a year earlier. Against the prior quarter it is down 14.8%.

DVAX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DVAX quarterly income statement

Metric	TTM	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Revenue	$330.5M	$277.2M+19.4%	$232.3M-67.9%	$722.7M+64.5%	$439.4M+844.0%	$46.6M+32.2%	$35.2M+329.6%	$8.2M+2407.0%	$327K-97.0%	$11.0M+172.7%	$4.0M-63.3%	$11.0M-1.9%	$11.3M+15.8%	$9.7M-55.1%	$21.6M-9.8%	$23.9M
Cost of Revenue	$55.6M	$49.4M-1.4%	$50.2M-80.9%	$262.2M+51.0%	$173.6M+1421.2%	$11.4M+12.2%	$10.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$274.9M	$227.8M+25.1%	$182.1M-60.5%	$460.5M+73.2%	$265.9M+656.6%	$35.1M+40.3%	$25.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$73.8M	$61.5M+12.1%	$54.9M+17.8%	$46.6M+44.6%	$32.2M+12.7%	$28.6M-54.1%	$62.3M-16.8%	$75.0M+15.3%	$65.0M-23.1%	$84.5M-2.8%	$86.9M+2.8%	$84.6M+66.3%	$50.9M+3.5%	$49.1M-4.2%	$51.3M-4.4%	$53.7M
SG&A Expenses	$179.7M	$170.4M+11.4%	$152.9M+16.4%	$131.4M+31.2%	$100.2M+26.4%	$79.3M+5.7%	$75.0M+15.8%	$64.8M+136.7%	$27.4M-26.5%	$37.3M+68.0%	$22.2M+27.6%	$17.4M-33.0%	$25.9M-7.9%	$28.2M+60.3%	$17.6M+4.1%	$16.9M
Operating Income	$10.4M	-$4.1M+88.9%	-$37.0M-113.1%	$283.5M+110.8%	$134.5M+296.7%	-$68.4M+49.3%	-$134.8M+12.1%	-$153.3M-59.7%	-$96.0M+13.3%	-$110.7M-5.4%	-$105.1M-15.1%	-$91.3M-37.3%	-$66.5M+1.6%	-$67.6M-42.1%	-$47.6M0.0%	-$47.6M
EBITDA	N/A	$505K+101.5%	-$32.7M-111.4%	$287.3M+107.0%	$138.8M+316.5%	-$64.1M+49.1%	-$125.9M+15.9%	-$149.7M-61.4%	-$92.8M+14.5%	-$108.5M-4.6%	-$103.7M-15.4%	-$89.9M-38.0%	-$65.2M+1.8%	-$66.4M-43.5%	-$46.3M-0.2%	-$46.2M
Interest Expense	$6.7M	$6.8M+0.5%	$6.8M+0.4%	$6.7M-39.8%	$11.2M-41.4%	$19.1M+12.3%	$17.0M+81.8%	$9.3M	N/A	N/A	$572K+1534.3%	$35K	N/A	$2.4M+20.1%	$2.0M+18.3%	$1.7M
Income Tax	$2.8M	$3.5M+75.4%	$2.0M+76.9%	$1.1M+41.5%	$808K	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	N/A
Net Income	-$43.4M	$27.3M+527.4%	-$6.4M-102.2%	$293.2M+282.1%	$76.7M+202.0%	-$75.2M+50.7%	-$152.6M+4.0%	-$158.9M-67.0%	-$95.2M+15.4%	-$112.4M-5.3%	-$106.8M-17.7%	-$90.7M-36.0%	-$66.7M+4.6%	-$69.9M-43.9%	-$48.6M+15.2%	-$57.3M
EPS (Basic)	N/A	$0.21+520.0%	-$0.05-102.2%	$2.32+274.2%	$0.62+182.7%	-$0.75+65.3%	-$2.16+15.3%	-$2.55	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.37	$0.20+500.0%	-$0.05-102.5%	$1.97+245.6%	$0.57+173.1%	-$0.78+63.9%	-$2.16+15.3%	-$2.55	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	133M+3.6%	129M-14.6%	151M+13.4%	133M+31.0%	102M+40.9%	72M+15.5%	62M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K
Revenue	$94.9M+17.7%	$95.4M+29.3%	$68.2M+34.2%	$72.0M+29.6%	$80.6M+16.0%	$73.8M+22.5%	$50.8M+8.2%	$55.6M-69.9%
Cost of Revenue	$14.4M+10.1%	$14.0M+17.1%	$13.8M+25.6%	$13.4M+54.3%	$13.1M-1.1%	$12.0M-11.5%	$11.0M-25.5%	$8.7M-88.8%
Gross Profit	$80.5M+19.1%	$81.4M+31.7%	$54.4M+36.6%	$58.6M+25.0%	$67.5M+20.0%	$61.8M+32.3%	$39.8M+23.6%	$46.9M-56.2%
R&D Expenses	$19.1M+32.7%	$16.6M+11.2%	$19.4M+43.2%	$18.7M+32.2%	$14.4M+2.0%	$14.9M+14.6%	$13.5M-0.6%	$14.1M+9.8%
SG&A Expenses	$40.1M-6.9%	$50.4M+20.9%	$47.7M+8.2%	$41.6M+0.7%	$43.1M+13.2%	$41.7M+12.4%	$44.1M+20.6%	$41.3M+33.1%
Operating Income	$21.3M+111.0%	$14.4M+177.6%	-$23.6M-33.0%	-$1.6M+80.8%	$10.1M+97.1%	$5.2M+252.7%	-$17.8M+41.3%	-$8.5M-113.4%
EBITDA	$22.6M+100.3%	$15.7M+147.4%	-$22.5M-34.9%	-$449K+93.9%	$11.3M+80.8%	$6.3M+374.8%	-$16.6M+43.1%	-$7.4M-111.5%
Interest Expense	$1.6M-3.3%	$1.6M-3.4%	$1.7M-0.2%	$1.7M+0.6%	$1.7M+0.5%	$1.7M+0.6%	$1.7M+0.5%	$1.7M+0.5%
Income Tax	$1.5M-32.9%	$2.5M-29.1%	-$1.8M+36.0%	$578K-25.6%	$2.2M+1612.9%	$3.5M+353.6%	-$2.8M-550.6%	$777K+222.4%
Net Income	$26.9M+53.0%	$18.7M+64.4%	-$96.1M-1001.9%	$7.0M+3119.2%	$17.6M+23.1%	$11.4M+231.9%	-$8.7M+64.2%	$219K-99.7%
EPS (Basic)	$0.23+76.9%	$0.16+77.8%	-$0.77-1000.0%	$0.06	$0.13+18.2%	$0.09+200.0%	-$0.07+63.2%	$0.00-100.0%
EPS (Diluted)	$0.21+75.0%	$0.14+75.0%	-$0.77-1000.0%	$0.05	$0.12+20.0%	$0.08+166.7%	-$0.07+63.2%	$0.00-100.0%
Diluted Shares (Avg)	136M-11.8%	138M-10.4%	125M-4.1%	N/A	155M+0.4%	154M+1.5%	130M+1.8%	N/A

DVAX Balance Sheet

DVAX quarterly balance sheet

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Total Assets	$986.3M-1.1%	$997.1M+1.1%	$985.9M-5.1%	$1.0B+194.2%	$353.3M+26.6%	$279.1M+32.3%	$210.9M-3.6%	$218.8M+99.5%	$109.7M-49.4%	$216.6M+56.7%	$138.3M-32.4%	$204.6M+46.4%	$139.8M+4.2%	$134.1M+59.2%	$84.2M
Current Assets	$848.9M-1.2%	$859.1M-6.3%	$917.0M-5.7%	$972.5M+235.3%	$290.0M+39.0%	$208.7M+19.7%	$174.4M-11.9%	$198.0M+121.0%	$89.6M-55.2%	$199.9M+56.9%	$127.4M-33.8%	$192.4M+50.1%	$128.2M+2.9%	$124.6M+67.2%	$74.5M
Cash & Equivalents	$95.9M-36.2%	$150.3M-25.6%	$202.0M-53.7%	$436.2M+1260.0%	$32.1M-19.6%	$39.9M-19.2%	$49.3M+85.6%	$26.6M+9.4%	$24.3M-45.8%	$44.8M-9.5%	$49.5M+114.1%	$23.1M+204.3%	$7.6M-76.2%	$31.9M+42.3%	$22.5M
Short-Term Investments	$618.0M+4.4%	$592.0M+40.2%	$422.4M+284.8%	$109.8M-17.4%	$133.0M+19.6%	$111.2M+15.6%	$96.2M-41.8%	$165.3M+189.3%	$57.1M-62.2%	$151.3M+106.9%	$73.1M-56.0%	$166.3M+41.5%	$117.5M+43.3%	$82.0M+65.0%	$49.7M
Inventory	$70.1M+31.5%	$53.3M-10.4%	$59.4M-3.1%	$61.3M-3.7%	$63.7M+54.1%	$41.3M+117.3%	$19.0M+5996.8%	$312K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.4M+91.7%	$727K-55.3%	$1.6M+61.9%	$1.0M-89.5%	$9.5M+851.7%	$1.0M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$1.9M-5.9%	$2.1M+3.0%	$2.0M-5.6%	$2.1M-7.5%	$2.3M+10.4%	$2.1M-2.9%	$2.1M-4.5%	$2.2M+13.9%	$2.0M-3.5%	$2.0M-10.3%	$2.3M-11.7%	$2.6M+4.2%	$2.5M+7.1%	$2.3M0.0%	$2.3M
Total Liabilities	$389.5M+3.8%	$375.0M-7.4%	$404.8M-50.4%	$816.9M+177.3%	$294.6M+8.8%	$270.8M+83.2%	$147.8M+668.4%	$19.2M-6.1%	$20.5M-30.7%	$29.6M-21.8%	$37.8M+106.3%	$18.3M-26.5%	$24.9M-27.2%	$34.2M+6.5%	$32.1M
Current Liabilities	$78.6M+26.4%	$62.2M-58.6%	$150.1M-73.0%	$556.4M+618.8%	$77.4M+45.9%	$53.0M+39.5%	$38.0M+104.6%	$18.6M-7.2%	$20.0M-30.4%	$28.8M+41.9%	$20.3M+25.2%	$16.2M-14.8%	$19.0M-30.1%	$27.2M+95.6%	$13.9M
Non-Current Liabilities	$310.8M-0.6%	$312.8M+22.8%	$254.8M-2.2%	$260.5M+19.9%	$217.2M-0.3%	$217.7M+98.3%	$109.8M+16974.0%	$643K+45.1%	$443K-42.4%	$769K-95.6%	$17.5M+720.6%	$2.1M-63.9%	$5.9M-15.6%	$7.0M-61.6%	$18.2M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$179.8M+0.7%	$178.6M+77.1%	$100.9M	N/A	N/A	N/A	$9.6M	N/A	N/A	N/A	N/A
Total Equity	$596.8M-4.1%	$622.1M+7.1%	$581.0M+161.3%	$222.4M+278.9%	$58.7M+608.0%	$8.3M-86.9%	$63.1M-68.4%	$199.5M+123.7%	$89.2M-52.3%	$187.1M+86.2%	$100.5M-46.1%	$186.3M+62.2%	$114.8M+15.0%	$99.9M+91.7%	$52.1M
Retained Earnings	-$903.3M+2.9%	-$930.6M-0.7%	-$924.2M+24.1%	-$1.2B+5.9%	-$1.3B-6.2%	-$1.2B-14.3%	-$1.1B-17.5%	-$907.3M-11.7%	-$812.2M-16.1%	-$699.7M-18.0%	-$592.9M-18.1%	-$502.2M-15.3%	-$435.5M-19.1%	-$365.5M-15.3%	-$316.9M

Metric	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K
Total Assets	$946.5M-10.9%	$918.4M-9.6%	$945.9M-4.1%	$986.3M-1.1%	$1.1B+9.2%	$1.0B+8.5%	$986.6M+1.7%	$997.1M+1.1%
Current Assets	$814.3M-12.1%	$785.7M-10.9%	$816.0M-4.1%	$848.9M-1.2%	$926.2M+10.8%	$882.0M+10.6%	$851.3M+2.5%	$859.1M-6.3%
Cash & Equivalents	$160.2M+34.3%	$99.1M-11.9%	$51.7M-60.8%	$95.9M-36.2%	$119.3M-22.8%	$112.5M-50.4%	$132.0M-24.3%	$150.3M-25.6%
Short-Term Investments	$487.6M-24.4%	$514.6M-17.4%	$609.6M+3.1%	$618.0M+4.4%	$644.7M+13.9%	$623.1M+37.0%	$591.5M+23.8%	$592.0M+40.2%
Inventory	$73.3M+17.4%	$75.7M+21.2%	$74.4M+20.4%	$70.1M+31.5%	$62.4M+26.3%	$62.5M+17.7%	$61.8M+7.1%	$53.3M-10.4%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$2.2M+5.2%	$2.2M+9.6%	$2.0M+0.2%	$1.9M-5.9%	$2.1M+5.6%	$2.0M-1.6%	$2.0M-0.8%	$2.1M+3.0%
Total Liabilities	$412.4M+8.4%	$424.3M+13.6%	$415.0M+12.7%	$389.5M+3.8%	$380.6M+3.4%	$373.5M+4.0%	$368.1M-9.4%	$375.0M-7.4%
Current Liabilities	$106.8M+52.6%	$118.2M+90.1%	$68.4M+22.1%	$78.6M+26.4%	$70.0M+29.1%	$62.2M+38.6%	$56.0M-38.8%	$62.2M-58.6%
Non-Current Liabilities	$305.5M-1.6%	$306.1M-1.7%	$346.6M+11.1%	$310.8M-0.6%	$310.5M-1.0%	$311.3M-1.0%	$312.1M-0.8%	$312.8M+22.8%
Total Equity	$534.1M-21.6%	$494.2M-23.1%	$530.9M-14.2%	$596.8M-4.1%	$681.4M+12.6%	$642.8M+11.4%	$618.5M+9.7%	$622.1M+7.1%
Retained Earnings	-$953.7M-4.8%	-$980.7M-5.7%	-$999.4M-6.4%	-$903.3M+2.9%	-$910.3M+2.2%	-$927.9M+1.8%	-$939.3M+1.0%	-$930.6M-0.7%

Not reported in any period shown, so not listed: Accounts Receivable, Long-Term Debt.

DVAX Cash Flow Statement

DVAX quarterly cash flow statement

Metric	TTM	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Operating Cash Flow	$90.6M	$66.5M-33.9%	$100.6M+60.3%	$62.7M-81.3%	$335.5M+463.7%	-$92.3M+23.9%	-$121.3M+7.7%	-$131.3M-69.4%	-$77.5M+27.6%	-$107.1M-15.7%	-$92.6M-25.5%	-$73.7M-25.7%	-$58.7M-33.9%	-$43.8M+7.0%	-$47.1M+8.3%	-$51.4M
Depreciation & Amortization	N/A	$4.6M+6.6%	$4.3M+13.9%	$3.8M-11.3%	$4.3M+0.5%	$4.3M-52.2%	$8.9M+146.8%	$3.6M+11.6%	$3.2M+43.7%	$2.3M+65.3%	$1.4M-2.8%	$1.4M+5.8%	$1.3M+9.9%	$1.2M-7.4%	$1.3M-7.9%	$1.4M
Stock-Based Compensation	N/A	$52.6M+23.5%	$42.6M+29.4%	$32.9M+54.6%	$21.3M+57.9%	$13.5M-47.0%	$25.5M+8.4%	$23.5M+57.4%	$14.9M+5.6%	$14.1M+51.6%	$9.3M+53.0%	$6.1M-50.7%	$12.3M+18.2%	$10.4M+101.2%	$5.2M+115.3%	$2.4M
Capital Expenditures	$10.1M	$6.4M+54.8%	$4.1M-42.5%	$7.1M-24.7%	$9.5M+132.7%	$4.1M-81.8%	$22.4M+435.0%	$4.2M+525.9%	$669K-91.4%	$7.8M+11.3%	$7.0M+318.1%	$1.7M+2.3%	$1.6M-44.4%	$2.9M+156.7%	$1.1M+171.9%	$420K
Free Cash Flow	$80.5M	$60.2M-37.6%	$96.5M+73.6%	$55.6M-83.0%	$326.1M+438.5%	-$96.3M+32.9%	-$143.7M-6.0%	-$135.5M-73.3%	-$78.2M+31.9%	-$114.8M-15.4%	-$99.5M-32.0%	-$75.4M-25.0%	-$60.3M-29.0%	-$46.7M+3.1%	-$48.3M+6.8%	-$51.8M
Investing Cash Flow	$152.4M	-$18.0M+88.3%	-$153.9M+51.3%	-$316.0M-2321.4%	$14.2M+153.6%	-$26.5M+38.0%	-$42.8M-177.1%	$55.5M+151.0%	-$108.7M-226.0%	$86.2M	N/A	N/A	-$51.4M-29.4%	-$39.7M-14.7%	-$34.6M+31.5%	-$50.5M
Financing Cash Flow	-$202.7M	-$102.0M-7460.5%	$1.4M-92.9%	$19.5M-65.0%	$55.8M-49.1%	$109.5M-29.1%	$154.4M+55.8%	$99.1M-47.3%	$187.8M+35275.1%	$531K	N/A	N/A	$125.4M+112.4%	$59.0M-35.4%	$91.4M+4.3%	$87.6M
Share Buybacks	$201.2M	$100.0M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K
Operating Cash Flow	$33.8M+73.8%	$23.4M+118.7%	-$19.6M-17.7%	$53.0M+285.1%	$19.5M-37.5%	$10.7M-61.8%	-$16.7M-160.4%	$13.8M-60.6%
Depreciation & Amortization	$1.3M+9.0%	$1.2M+9.4%	$1.2M+4.4%	$1.2M+6.3%	$1.2M+6.2%	$1.1M+3.2%	$1.1M+11.0%	$1.1M+33.1%
Stock-Based Compensation	N/A	N/A	$14.5M+11.1%	N/A	N/A	N/A	$13.0M+29.7%	N/A
Capital Expenditures	$1.2M-8.1%	$1.5M+86.4%	$3.9M+424.4%	$3.5M+101.9%	$1.3M+287.9%	$779K+3.7%	$749K-41.6%	$1.7M+8.6%
Free Cash Flow	$32.6M+79.9%	$22.0M+121.3%	-$23.6M-35.2%	$49.5M+311.3%	$18.1M-41.1%	$9.9M-63.6%	-$17.4M-166.2%	$12.0M-63.9%
Investing Cash Flow	$27.3M+276.7%	$94.8M+429.5%	$6.9M+144.1%	$23.4M+215.4%	-$15.5M+85.4%	-$28.8M-216.4%	$2.8M+105.4%	-$20.2M+38.6%
Financing Cash Flow	-$61K-102.5%	-$71.9M-4982.5%	-$31.9M-658.6%	-$98.9M-5667.3%	$2.5M-17.3%	-$1.4M-381.3%	-$4.2M-36.0%	$1.8M+1060.8%
Share Buybacks	$572K	$71.2M	$29.5M	$100.0M	$0	$0	$0	N/A

Not reported in any period shown, so not listed: Dividends Paid.

DVAX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DVAX quarterly financial ratios

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Gross Margin	82.2%+3.8pp	78.4%+14.7pp	63.7%+3.2pp	60.5%-15.0pp	75.5%+4.4pp	71.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1.5%+14.4pp	-15.9%-55.2pp	39.2%+8.6pp	30.6%	-146.9%	-382.9%	-1870.2%	-29359.3%	-1002.5%	-2594.4%	-827.7%	-591.0%	-695.9%	-220.1%	-198.7%
Net Margin	9.8%+12.6pp	-2.8%-43.3pp	40.6%+23.1pp	17.5%	-161.6%	-433.3%	-1938.3%	-29099.1%	-1018.2%	-2636.9%	-822.3%	-593.0%	-720.1%	-224.8%	-239.3%
Return on Equity	4.6%+5.6pp	-1.0%-51.5pp	50.5%+16.0pp	34.5%+162.7pp	-128.2%+1712.6pp	-1840.8%-1588.8pp	-252.0%-204.3pp	-47.7%+78.4pp	-126.1%-69.0pp	-57.1%+33.2pp	-90.3%-54.5pp	-35.8%+25.1pp	-60.9%-12.3pp	-48.7%+61.3pp	-110.0%
Return on Assets	2.8%+3.4pp	-0.6%-30.4pp	29.7%+22.4pp	7.4%+28.7pp	-21.3%+33.4pp	-54.7%+20.7pp	-75.3%-31.9pp	-43.5%+59.0pp	-102.5%-53.2pp	-49.3%+16.3pp	-65.6%-33.0pp	-32.6%+17.4pp	-50.0%-13.8pp	-36.2%+31.8pp	-68.0%
Current Ratio	10.80-3.0x	13.81+7.7x	6.11+4.4x	1.75-2.0x	3.75-0.2x	3.93-0.7x	4.58-6.1x	10.65+6.2x	4.47-2.5x	6.95+0.7x	6.28-5.6x	11.88+5.1x	6.74+2.2x	4.58-0.8x	5.35
Debt-to-Equity	0.650.0x	0.60-0.1x	0.70+0.7x	0.00-3.1x	3.06-18.5x	21.54+19.9x	1.60+1.5x	0.10-0.1x	0.23+0.1x	0.16+0.1x	0.100.0x	0.10-0.1x	0.22-0.1x	0.34-0.3x	0.62
Asset Turnover	0.280.0x	0.23-0.5x	0.73+0.3x	0.42+0.3x	0.130.0x	0.13+0.1x	0.040.0x	0.00-0.1x	0.10+0.1x	0.02-0.1x	0.080.0x	0.060.0x	0.07-0.1x	0.16-0.1x	0.28
FCF Margin	21.7%-19.8pp	41.5%+33.8pp	7.7%-66.5pp	74.2%	-206.9%	-407.9%	-1652.7%	-23910.4%	-1039.6%	-2457.5%	-683.5%	-536.0%	-481.2%	-223.3%	-216.2%

Metric	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K
Gross Margin	84.8%+1.0pp	85.3%+1.5pp	79.8%+1.4pp	81.4%-3.0pp	83.8%+2.8pp	83.8%+6.2pp	78.4%+9.8pp	84.4%+26.4pp
Operating Margin	22.4%+9.9pp	15.1%+8.1pp	-34.7%+0.3pp	-2.3%+13.0pp	12.5%+5.1pp	7.0%+12.7pp	-35.0%+29.5pp	-15.3%-49.5pp
Net Margin	28.4%+6.6pp	19.6%+4.2pp	-141.0%	9.8%+9.4pp	21.8%+1.3pp	15.4%+9.7pp	-17.2%+34.7pp	0.4%-36.3pp
Return on Equity	5.0%+2.5pp	3.8%+2.0pp	-18.1%-16.7pp	1.2%+1.1pp	2.6%+0.2pp	1.8%+1.2pp	-1.4%+2.9pp	0.0%-11.6pp
Return on Assets	2.8%+1.2pp	2.0%+0.9pp	-10.2%-9.3pp	0.7%+0.7pp	1.7%+0.2pp	1.1%+0.8pp	-0.9%+1.6pp	0.0%-6.8pp
Current Ratio	7.62-5.6x	6.65-7.5x	11.93-3.3x	10.80-3.0x	13.23-2.2x	14.18-3.6x	15.20+6.1x	13.81+7.7x
Debt-to-Equity	0.77+0.2x	0.86+0.3x	0.78+0.2x	0.650.0x	0.560.0x	0.580.0x	0.60-0.1x	0.60-0.1x
Asset Turnover	0.100.0x	0.100.0x	0.070.0x	0.070.0x	0.080.0x	0.070.0x	0.050.0x	0.06-0.1x
FCF Margin	34.4%+11.9pp	23.0%+9.6pp	-34.6%-0.3pp	68.8%+47.1pp	22.5%-21.8pp	13.5%-31.8pp	-34.3%-90.4pp	21.7%+3.6pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Dynavax Technologies Corporation DVAX	FY2024	$277.2M	$27.3M	9.8%	$1.8B	54/100
Pacira BioSciences, Inc. PCRX	FY2025	$726.4M	$7.0M	1.0%	$1.0B	53/100
Tilray Brands, Inc. TLRY	FY2026	$915.5M	-$121.4M	-13.3%	$553.1M	37/100
Amphastar Pharmaceuticals, Inc. AMPH	FY2025	$719.9M	$98.1M	13.6%	$1.0B	70/100
Collegium Pharmaceutical, Inc. COLL	FY2025	$780.6M	$63.0M	8.1%	$740.6M	65/100

Where Dynavax Technologies Corporation Ranks

Frequently Asked Questions

What is Dynavax Technologies Corporation's annual revenue?

Dynavax Technologies Corporation (DVAX) reported $277.2M in total revenue for fiscal year 2024. This represents a 19.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Dynavax Technologies Corporation's revenue growing?

Dynavax Technologies Corporation (DVAX) revenue grew by 19.4% year-over-year, from $232.3M to $277.2M in fiscal year 2024.

Is Dynavax Technologies Corporation profitable?

Yes, Dynavax Technologies Corporation (DVAX) reported a net income of $27.3M in fiscal year 2024, with a net profit margin of 9.8%.

What is Dynavax Technologies Corporation's EBITDA?

Dynavax Technologies Corporation (DVAX) had EBITDA of $505K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Dynavax Technologies Corporation's gross margin?

Dynavax Technologies Corporation (DVAX) had a gross margin of 82.2% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Dynavax Technologies Corporation's operating margin?

Dynavax Technologies Corporation (DVAX) had an operating margin of -1.5% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Dynavax Technologies Corporation's net profit margin?

Dynavax Technologies Corporation (DVAX) had a net profit margin of 9.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Dynavax Technologies Corporation's return on equity (ROE)?

Dynavax Technologies Corporation (DVAX) has a return on equity of 4.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Dynavax Technologies Corporation's free cash flow?

Dynavax Technologies Corporation (DVAX) generated $60.2M in free cash flow during fiscal year 2024. This represents a -37.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Dynavax Technologies Corporation's operating cash flow?

Dynavax Technologies Corporation (DVAX) generated $66.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Dynavax Technologies Corporation's total assets?

Dynavax Technologies Corporation (DVAX) had $986.3M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Dynavax Technologies Corporation's capital expenditures?

Dynavax Technologies Corporation (DVAX) invested $6.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Dynavax Technologies Corporation spend on research and development?

Dynavax Technologies Corporation (DVAX) invested $61.5M in research and development during fiscal year 2024.

Does Dynavax Technologies Corporation buy back shares?

Yes, Dynavax Technologies Corporation (DVAX) spent $100.0M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

How many shares does Dynavax Technologies Corporation have outstanding?

Dynavax Technologies Corporation (DVAX) had 124M shares outstanding as of fiscal year 2024.

What is Dynavax Technologies Corporation's current ratio?

Dynavax Technologies Corporation (DVAX) had a current ratio of 10.80 as of fiscal year 2024, which is generally considered healthy.

What is Dynavax Technologies Corporation's debt-to-equity ratio?

Dynavax Technologies Corporation (DVAX) had a debt-to-equity ratio of 0.65 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Dynavax Technologies Corporation's return on assets (ROA)?

Dynavax Technologies Corporation (DVAX) had a return on assets of 2.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Dynavax Technologies Corporation's Altman Z-Score?

Dynavax Technologies Corporation (DVAX) has an Altman Z-Score of 2.73, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Dynavax Technologies Corporation's Piotroski F-Score?

Dynavax Technologies Corporation (DVAX) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Dynavax Technologies Corporation's earnings high quality?

Dynavax Technologies Corporation (DVAX) has an earnings quality ratio of 2.44x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Dynavax Technologies Corporation cover its interest payments?

Dynavax Technologies Corporation (DVAX) reported an operating loss of $4.1M against $6.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Dynavax Technologies Corporation?

Dynavax Technologies Corporation (DVAX) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.